Pancreatic beta-cell replacement therapy in the treatment of type 1 diabetes mellitus  – achievements and future research policy

Katarzyna Żełobowska; Janusz Gumprecht; Władysław Grzeszczak

ISSN: 1505-8409

Przewodnik Lekarza/Guide for GPs

Current issue Archive About the journal Supplements Abstracting and indexing Contact Instructions for authors

3/2008
vol. 11

Send email

Copy url:

abstract:

Pancreatic beta-cell replacement therapy in the treatment of type 1 diabetes mellitus – achievements and future research policy

Katarzyna Żełobowska

,

Janusz Gumprecht

,

Władysław Grzeszczak

Przew Lek 2008; 3: 45-54

Online publish date: 2008/07/11

View full text Get citation

Beta-cell replacement therapy, a whole pancreas as well as pancreatic islets transplantation, is nowadays the only one that restores the physiological endogenous insulin secretion in patients with type 1 diabetes mellitus. Beside unquestionable benefits both methods create a risk of complications, requiring future studies in order to be eliminated, and considering an increasing amount of transplantation procedures an insufficient number of organ donors may become a real problem. The future of diabetes therapy depends on the progress in new immunosuppressive and/or immunomodulatory therapy, alternative sources of pancreatic islets and transplantation strategies development.

keywords:

Pancreatic beta-cell replacement therapy in the treatment of type 1 diabetes mellitus – achievements and future research policy

Katarzyna Żełobowska , Janusz Gumprecht , Władysław Grzeszczak

diabetes mellitus, transplantation, beta-cell

Katarzyna Żełobowska

,

Janusz Gumprecht

,

Władysław Grzeszczak